<DOC>
	<DOCNO>NCT00958750</DOCNO>
	<brief_summary>The purpose study determine woman risk/benefit profile non-inferiority topical 5 % Minoxidil foam formulation apply daily treatment androgenetic alopecia comparison 2 % MTS use twice daily , use objective subjective efficacy measure safety assessment study period 24 week .</brief_summary>
	<brief_title>Efficacy Safety Study Compare Two Minoxidil Formulations Women With Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<criteria>Female , age 18 old , general good health Exhibits AGA base discernable decrease hair density top scalp , relative side back scalp , scalp hair density involve area D3 D6 Savin Density Scale ( See Appendix 1 ) Hair density equal le 220 hair /cm2 measure TrichoScan Subjects give consent study thoroughly clarification personally sign date informed consent document indicate subject ( legally acceptable representative ) , inform pertinent aspect trial Women childbearing potential , practice effective method contraception least five consecutive week prior study entry study one follow method : Double contraceptive method among hormonal contraception ( e.g . contraceptive pill , intra uterine device , vaginal ring , injectable implantable contraception ) , spermicide , condom diaphragm . Oral/systemic contraception must past 6 month change study Sexual abstinence Partner vasectomy ( date back 6 month ) OR Women nonchildbearing potential , i. e. postmenopausal ( absence menstrual bleeding 2 year ) , hysterectomy , bilateral tubal ligation bilateral ovariectomy Women childbearing potential must show negative urine pregnancy test Screening Willing maintain hairstyle , hair length hair color throughout study Subjects willing able comply schedule visit , treatment plan , minitattoo , laboratory test trial procedure . Known hypersensitive Minoxidil , hair dye ( PPhenylendiamin ) , Tattoo ink , propylene glycol , fragrance , hair gel vehicle component . Current 4 week date back use local treatment ( drug cosmetically ) target region interfere study product examination method ( corticosteroid , Aminexil , Minoxidil , medical shampoo , topical estrogen , Ketoconazol ) Current 3 month date back use systemic treatment ( drug dietary supplement ) take 2 consecutive week interfere study product examination method ( beta blocker , Cimetidine , Diazoxid , Isotretinoin , corticosteroid , vitamin A intake 10000 IU per day ) Within past 6 month receive chemotherapy/cytotoxic agent well radiation and/or laser/surgical therapy scalp Current prior enrollment investigational medication ( drug ) study within last 4 week Women childbearing potential insufficient contraception . Female pregnant , planning pregnancy ( course study ) nursing child Presence hair transplant , hair weave nonbreathable wig Any dermatological disorder scalp target region possibility interfere study product examination method , fungal bacterial infection , seborrheic dermatitis , psoriasis , eczema , folliculitis , scar scalp atrophy Active hair loss history within past 3 month include diffuse telogen effluvium , alopecia areata , scar alopecia androgen hair loss /hyperandrogenemia ) Other severe , acute chronic medical condition may lead hair loss interfere interpretation trial result Individuals institutionalized court regulatory order</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Androgenetic alopecia</keyword>
	<keyword>female pattern hair loss</keyword>
</DOC>